About the company
Royalty Pharma PLC, a leading player in the biopharmaceutical industry, has established itself as a prominent buyer of biopharmaceutical royalties and a key funder of innovation. With a unique approach to investment, the company has built a robust portfolio of royalties that entitle it to payments directly linked to the top-line sales of numerous therapies. The success of Royalty Pharma PLC lies in its ability to identify and acquire royalties on some of the industry's most groundbreaking and commercially successful products. With over 35 commercial products in its portfolio, the company enjoys a diverse range of revenue streams. Notably, it holds royalties on game-changing therapies such as Imbruvica, developed by AbbVie and Johnson & Johnson, which has revolutionized the treatment of certain types of cancer. Another significant asset in Royalty Pharma PLC's repertoire is Xtandi, a joint effort by Astellas and Pfizer. Xtandi has extended the lifespan and improved the quality of life for patients battling advanced prostate cancer, reinforcing the company's commitment to supporting innovative treatments that make a substantial impact on patients' lives. Biogen's Tysabri, renowned for its effectiveness in treating multiple sclerosis, is yet another valuable asset in Royalty Pharma PLC's ever-expanding portfolio. Through its royalties on this therapy, the company contributes to the advancement of treatments for a debilitating disease that affects millions worldwide. Tremfya, developed by Johnson & Johnson, has also caught the attention of Royalty Pharma PLC. This groundbreaking therapy has brought hope and relief to patients suffering from psoriasis, a chronic autoimmune condition that affects the skin. By investing in royalties on Tremfya, the company supports research and development efforts to combat the challenges posed by this complex disease. Royalty Pharma PLC has also recognized the potential of Gilead's Trodelvy in transforming the landscape of cancer treatment. This innovative therapy has demonstrated remarkable efficacy in combating certain types of advanced or metastatic cancers, positioning it as a valuable asset in the company's investment portfolio. Merck's Januvia, Novartis' Promacta, Vertex's Kalydeco, Orkambi, Symdeko, and Trikafta are additional notable additions to Royalty Pharma PLC's expansive arsenal of royalties. These products have revolutionized the treatment of various conditions, ranging from type 2 diabetes to cystic fibrosis. By securing royalties on these therapies, the company continues to foster innovation and contribute to the advancement of patient care. In addition to its impressive collection of royalties on existing commercial products, Royalty Pharma PLC also maintains a keen eye on the future. The company has invested in ten development-stage product candidates, recognizing the potential for groundbreaking therapies that may soon shape the biopharmaceutical landscape. With its strategic acquisitions and extensive portfolio, Royalty Pharma PLC has solidified its position as a major player in the biopharmaceutical industry. By purchasing biopharmaceutical royalties and providing crucial funding for research and development, the company actively promotes innovation and advances in patient care. As it continues to expand its investments and support game-changing therapies, Royalty Pharma PLC plays a vital role in revolutionizing the field of biopharmaceuticals, ultimately benefiting patients around the world.
Website: https://www.royaltypharma.com
Data updated: May 5, 2026
